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ABSTRACT
Colorectal cancer (CRC) is one of the most common and lethal cancers worldwide. 
Despite recent progress, the prognosis of advanced stage CRC remains poor, mainly 
because of cancer recurrence and metastasis. The high morbidity and mortality of 
CRC has been recently ascribed to a small population of tumor cells that hold the 
potential of tumor initiation, i.e. cancer stem cells (CSCs), which play a pivotal role 
in cancer recurrence and metastasis and are not eradicated by current therapy. We 
screened CRC-SCs in vitro with a library of protein kinase inhibitors and showed 
that CRC-SCs are resistant to specific inhibition of the major signaling pathways 
involved in cell survival and proliferation. Nonetheless, broad-spectrum inhibition 
by the staurosporin derivative UCN-01 blocks CRC-SC growth and potentiates the 
activity of irinotecan in vitro and in vivo CRC-SC-derived models. Reverse-Phase 
Protein Microarrays (RPPA) revealed that, albeit CRC-SCs display individual phospho-
proteomic profiles, sensitivity of CRC-SCs to UCN-01 relies on the interference with 
the DNA damage response mediated by Chk1. Combination of LY2603618, a specific 
Chk1/2 inhibitor, with irinotecan resulted in a significant reduction of CRC-SC growth 
in vivo, confirming that irinotecan treatment coupled to inhibition of Chk1 represents 
a potentially effective therapeutic approach for CRC treatment.
INTRODUCTION
Colorectal cancer (CRC) is the third most frequent 
cancer in both sexes and is also the second cause of 
cancer death in the western world [1]. CRC development 
results from a progressive transformation of colorectal 
epithelial cells following the accumulation of mutations 
in a number of oncogenes and tumor suppressor genes [2]. 
Despite progress in surgery, radiation and chemotherapy, 
none of the treatments available is curative for patients 
with advanced stage CRC. Therefore, developing new 
therapeutic strategies to eliminate tumor is ultimately 
critical. The current standard treatment for advanced 
and metastatic colorectal cancer is represented by the 
combination of 5-fluorouracil (5-FU) and folates with 
oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) [3, 4], 
however the use of biologics directed to block some 
altered oncogenic pathways has also proven beneficial 
for a subset of patients. Cetuximab is an antibody that 
specifically blocks epidermal growth factor receptor 
(EGFR) oncogenic signaling in cancer cells. In association 
with conventional chemotherapy, Cetuximab has been 
shown to significantly increase the overall survival of 
patients with advanced colon cancer [5, 6]. Nonetheless 
almost 40% of CRC tumors bear KRAS-activating 
mutations and are refractory to Cetuximab treatment, 
indicating the relevance of genotyping tumors in order to 
select the most appropriate personalized treatment [7, 8].
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The stepwise accumulation of specific genetic 
lesions is known to exert a driving force in tumor 
progression and oftentimes underlies the resistance or 
sensitivity to specific targeted drugs. Drug resistance is 
also associated with an increased efficiency of protective 
mechanisms, e.g. drug efflux channels or DNA repair 
machinery [9, 10], which usually define a subpopulation 
of cancer cells endowed with stem-like features and thus 
named cancer stem cells (CSCs). CSCs are responsible for 
tumor initiation and maintenance due to their intrinsic self-
renewal capacity and the ability to differentiate, allowing 
the generation of a phenocopy of the original tumor upon 
injection into immunodeficient mice [11, 12]. Therefore, 
this subpopulation of cells represents a critical tool for the 
preclinical evaluation of new anticancer therapies. CRC 
cell lines have been widely used to investigate, both in vitro 
and in vivo, the genetic and epigenetic changes underlying 
tumor development as well as for drug screening and 
biomarker discovery studies [13-16]. In addition to the 
common advantages of commercially available colorectal 
cell lines, i.e. broad supply of live cells, ease of handling 
and controlling of experimental parameters, CRC-SC lines 
offer the unique opportunity to phenocopy the parental 
tumor and reproduce its transcriptional heterogeneity 
[17]. The establishment of improved preclinical models 
that recapitulate the human disease, preserving its cellular 
heterogeneity and histopathological or genetic alterations, 
is essential for testing the efficacy of new target-directed 
therapies and to identify drug response biomarkers [18]. 
In this study, we exploited two parallel experimental 
approaches, i.e. kinase inhibitor library screening and 
Reverse-Phase Protein Microarrays (RPPA) technology, to 
identify signaling pathways associated with the malignant 
behaviour of CRC-SC lines and evaluated the effects of 
interfering with them.
RESULTS
Isolation and characterization of colorectal 
cancer stem-like cell lines
Fifteen CRC-SC lines were obtained from 
colorectal adenocarcinoma patients. The main clinical 
characteristics of patients and the phenotypic features of 
the derived CRC-SC lines are listed in Supplementary 
Table S1. Tumor samples were subjected to mechanical 
and enzymatic dissociation and cultured in stem cell 
medium. All these CRC-SC lines were expanded in 
vitro and validated for their stem cell properties, by 
assessing the ability to self-renew, to generate progeny 
of multiple lineages in differentiating culture conditions 
and to faithfully reproduce patient's histology in mouse 
xenografts (Supplementary Figure S1). CRC-SC lines 
were also characterized for the expression of the stem 
cell marker CD133 and the epithelial marker Ber-Ep4 
[12] (Supplementary Table S1). Their authenticity was 
evaluated by analysis of the short tandem repeat (STR) 
profile. Moreover, we performed targeted sequencing 
of 17 tumor-specific genes in all CRC-SC lines. The 
frequency of genetic alterations in our CRC-SC line 
samples confirms that they are representative of the CRC 
patient population (Table 1).
CRC-SC lines display intrinsic resistance to 
small molecule kinase inhibitors
In order to identify molecular targets playing a major 
role in sustaining CRC-SC proliferation and survival, 
we first assessed the effect of a commercially available 
kinase inhibitor library on CRC-SC viability and/or 
proliferation. The drugs included in the screening library 
are low molecular weight protein kinase inhibitors (KI) 
targeting receptor tyrosine kinases (RTK), e.g. EGFR, 
and intracellular kinase pathways, e.g. PKC, considered 
important in cancer cell proliferation and/or survival. The 
complete list of the inhibitors and the pathways targeted is 
available in Supplementary Table S2. Staurosporine is the 
positive control of the library. Based on the knowledge in 
high-throughput screenings accumulated by pharmaceutical 
companies during the past decades [19], we decided to 
test the effect of each inhibitor at a single concentration (5 
μM) on 4 CRC-SC lines bearing either wild-type or mutant 
KRAS, and two KRAS mutant CRC commercial cell lines, 
HCT116 and SW480. After 48h treatment most of the 
compounds tested displayed low or no efficacy on the CRC-
SC lines (Figure 1A). A significant reduction of cell number 
below -1.5 x standard deviations (SD) from the overall 
mean viability was present, in all the cell lines, only for two 
drugs tested (Figure 1A). One of them, 5-iodotubercidin, 
is a multi-kinase inhibitor whereas Ro 31-8220 is a PKC 
inhibitor. Apart from one CRC-SC line, where the efficacy 
barely reached the -1.5 x SD threshold, Tyrphostin-9, a 
PDGFR inhibitor and Rottlerin, another PKC inhibitor 
that is more active on the δ iso-enzyme, were among the 
most effective drugs tested. Nonetheless, isolated inhibition 
of the pathways analyzed was not sufficient to efficiently 
and specifically interfere with CRC-SC survival and/or 
proliferation, with the possible exception of PKC, which is 
a broadly connected signaling hub [20]. Besides Rottlerin, 
several other chemicals exerted an inhibitory effect on 
CRC-SC viability but with a non-consistent pattern among 
the different cell lines, pointing primarily at EGFR, AKT, 
ERK and GSK3-β. In order to further evaluate the impact 
of the positive target hits on the viability of CRC-SCs or 
SW480 and HCT116 cell lines, we titrated down to 200 nM 
the compounds that in the initial screening led to a decrease 
in viability ≥ 1.5 x SD. The anti-proliferative activity of 
inhibitors of EGFR, GSK3-β and CaM kinase II was not 
maintained below 5 μM, irrespectively of KRAS mutation 
status. Conversely, a concentration-dependent effect was 
observed for at least one of the inhibitors acting against 
ERK, AKT, PDGFR and PKC (Figure 1B). Differently 
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from what observed for CRC-SCs at doses lower than 5 
μM, many of the selected compounds mantained their anti-
proliferative effects on SW480 and HCT116 cell lines even 
if at lesser extent (Figure 1B), suggesting that inhibition of 
targeted signaling pathways could be effective in eliminating 
the non-stem compartment of the tumor.
Multitarget inhibition by UCN-01 significantly 
impairs CRC-SC survival in vitro
To confirm the relevance of potential targets emerging 
from kinase inhibitor screening, we tested the efficacy of 
drug analogues on HCT116 and two representative CRC-
SC lines, i.e. #1.1 and #18, chosen based on their different 
KRAS and TP53 status. Although MEK inhibitors (U-
0126 and PD98059) did not show efficacy in the previous 
screening, as an experimental control we tested an analogue 
ATP-competitive inhibitor of ERK1 and ERK2 which, as 
expected, did not produce significant effects in the cell 
lines tested similarly to its negative control (Figure 2A). A 
significant decrease of CRC-SC viability was observed in 
experiments performed using a set of PKC-inhibitors and 
four different AKT-inhibitors (Figure 2A). While a clear 
efficacy of the DAG-binding competitor calphostin-C was 
evident, single inhibition of AKT was not sufficient to 
cause death in CRC-SC lines, reinforcing the concept that 
CSC survival and/or proliferation is driven by concomitant 
activation of multiple pathways. In line with this observation, 
the dual-pathway inhibitor PDK1/AKT/FLT showed 
significant effects in both CRC-SC lines. Nonetheless we 
explored the possibility to inhibit AKT pathway through a 
Celecoxib-derived compound that lacks cyclooxygenase-2 
(COX2) inhibitory activity and targets PDK1 (OSU-03012), 
without observing significant effects (Figure 2A). We also 
performed combinations of OSU-03012 with AKT-targeting 
compounds in order to reproduce the effects of the dual 
pathway inhibitor, but we could not observe synergistic 
effects (data not shown).
Among PKC inhibitors, we tested the staurosporine 
derivative UCN-01, which is a multi-kinase inhibitor that 
potently inhibits both AKT and PKC pathways (Figure 
2A). HCT116 cell line resulted more sensitive than CRC-
SC lines thus we decided to focus only on CRC-SCs for 
subsequent experiments. Since UCN-01 was effective on 
both CRC-SC lines tested (Figure 2A) we performed a 
dose-response curve assay on a wide panel of 15 CRC-SC 
lines (Figure 2B). After 72h of treatment, 11 of the cell 
lines showed a clear concentration-related inhibition of 
the proliferation with r2 above 0.58 and IC
50
 below 1 μM 
whereas 4 CRC-SCs showed resistance to the treatment 
(IC
50
 > 1μM, Table 2). We then tested the effect of UCN-
01 in combination with irinotecan, oxaliplatin or 5-FU, 
Table 1: Genetic alterations of 17 tumor-specific genes in CRC-SC lines
1.1 1.2 18 383 385 389 393 398 416 417 430 432 85 CRO 438
ACVR1B ∎ ∎ ∎
AMER1 ∎ ∎ ∎
APC ∎ ∎ ∎ ∎ ∎ ∎ ∎ ∎ ∎ ∎ ∎
BRAF ∎ ∎
CTNNB1 ∎ ∎ ∎ ∎ ∎ ∎
FBXW7 ∎ ∎ ∎ ∎ ∎
KIAA1804 ∎ ∎ ∎
KRAS ∎ ∎ ∎ ∎ ∎ ∎
MAP2K4 ∎ ∎
NRAS ∎ ∎ ∎
PIK3CA ∎ ∎ ∎ ∎ ∎ ∎ ∎ ∎ ∎ ∎
PTEN ∎ ∎ ∎
SMAD2 ∎ ∎ ∎ ∎
SMAD4 ∎ ∎ ∎ ∎ ∎ ∎ ∎
SOX9 ∎ ∎ ∎ ∎
TCF7L2 ∎ ∎ ∎ ∎ ∎ ∎
TP53 ∎ ∎ ∎ ∎ ∎ ∎ ∎ ∎
Criteria used to assigned mutations were: Allele Frequency >5%; SNP MAF <5%; Coverage >100x; Protein Damage 
Missense.
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Figure 1: CRC-SC lines are resistant to drug-mediated inhibition of diverse signaling pathways. A. For each non-SC and 
SC CRC-line results of drug response after 48h treatment with a small molecule kinase inhibitor library are reported as mean±SD (n=3) of 
standardized values (z score). Z scores were calculated from normalized viability values (VD, see Materials and Methods section) and the 
corresponding mean (mVD) and SD (sdVD) for each individual cell line using the following formula: z score=(VD–mVD)/sdVD. Dotted green 
and red horizontal lines denote the average (0) and -1.5 z scores, respectively. B. Titration of selected positive hits grouped by pathway 
target and other drugs included as experimental controls (individual drug names are indicated above each plot). Values are reported, for each 
cell line and drug tested, as the mean±SD of ≥2 independent experiments.
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Figure 2: Treatment of CRC-SCs with drug analogues of positive hits identifies UCN-01 as an anti-CSC agent that 
enhances the effects of chemotherapy in vitro. A. Titration of compounds analogue of drugs selected after screening with a kinase 
inhibitor library and resulting from dose-response tests in the low micromolar range. Drug names are reported on top of each plot and drugs 
sharing the same pathway targets are grouped in three boxes (AKT, ERK and PKC respectively). B. Dose-response curves of CRC-SCs 
after 72h of treatment with UCN-01. The mean±SD (n=3) and curve fitting lines are reported for each CRC-SC tested. C. Mean±SD (n=3) 
bar chart of 48h combinatorial treatment of UCN-01 and chemotherapeutic agents in 4 representative CRC-SC lines. Statistical comparison 
of UCN-01 alone versus UCN-01/irinotecan combination was done by means of Student’s t test and Bonferroni correction and is indicated 
on top of the relative bars. D. Western blot analysis of Caspase-3 and PARP cleavage after 48h single-agent UCN-01 and chemotherapy 
or combined treatments in wild-type (#1.1) or KRAS mutant (#18) CRC-SC lines. Drug concentrations were 5-FU: 25 μM, oxaliplatin: 10 
μM, irinotecan: 25 μM and UCN-01 500nM. Due to the different intensity of the signal, images of procaspase 3 (p32) and cleaved caspase 
3 fragments (p20-p17) belong to different time exposure.
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drugs included in standard chemotherapy protocols for 
colon cancer. UCN-01 treatment was extremely effective 
as a single agent in two out of four CRC-SC lines. The 
combination of UCN-01 with irinotecan, but not with 
oxaliplatin or 5-FU, produced a significantly stronger 
effect than UCN-01 alone in the two KRAS mutant CRC-
SC lines. Conversely, in the two KRAS wild-type CRC-
SC lines, the effect of the UCN-01/irinotecan combination 
was mostly due to irinotecan in the CRC-SC line #CRO-I 
and to UCN-01 in the CRC-SC line #1.1 (Figure 2C).
Finally, in two representative CRC-SCs treated with 
either oxaliplatin, irinotecan or 5-FU, given alone or in 
combination with UCN-01, we show that the cytotoxicity 
induced by UCN-01 combined or not with irinotecan is 
mediated by activation of caspase 3 in CRC-SC line #1.1, 
as assessed by the decrease of the full-length caspase 3 
(procaspase 3) and of its downstream target Poly-(ADP-
ribose) polymerase (PARP) (Figure 2D). Activation of 
caspase 3 was less evident in the KRAS mutant CRC-SC 
line #18 even though the combined treatment strongly 
reduced PARP. To investigate the possible contribution 
of other mechanisms of cell death, i.e. authophagy, we 
evaluated the expression of autophagosomal marker LC3-
II, which was not significantly modulated by treatment 
with UCN-01 in both CRC-SC lines (data not shown). 
The ability of UCN-01 to induce apoptosis alone or in 
combination with conventional drugs was evaluated 
by Annexin V/PI staining (Supplementary Figure S2). 
Treatment with UCN-01 alone or in combination with 
irinotecan increased the portion of Annexin V-positive 
cells compared to vehicle-treated cells, in both CRC-SC 
lines, irrespective of KRAS status. These results suggest 
that even in the KRAS mutant cell lines, UCN-01 alone or 
in combination with irinotecan is able to induce apoptosis 
at least in part mediated by a caspase 3-independent 
mechanism [21-24].
UCN-01 potentiates the ability of irinotecan to 
reduce tumor growth
Subcutaneous (s.c.) injection of CRC-SC lines 
into immunodeficient mice results in the generation of 
tumors bearing the phenotypic and histologic features 
of parental human counterparts (Supplementary Figure 
S1). Therefore, we assayed the effect of UCN-01 either 
alone or in combination with irinotecan, on s.c. tumors 
generated by injection of either #1.1, the most sensitive 
CRC-SC in in vitro drug combination experiments, or 
#18 the CRC-SC line in which additive effect of the 
combination was the most apparent in vitro. Compared 
to vehicle-treated controls, UCN-01 alone reduced 
the growth rate of the tumors at a greater extent than 
irinotecan alone while, the combination of the two 
agents resulted in increased efficacy when compared 
to single treatments (Figure 3). Differently from what 
observed in vitro, CRC-SC line #18 showed a sensitivity 
to single agent UCN-01 at least similar, if not higher, 
than line #1.1 (Figure 3).
Table 2: UCN-01 dose-response curve fitting data
CRC-SC # IC50 (nM) IC50 95% conf. int. (nM) R square
393 12.78 4.477 to 36.45 0.6922
1.1 48.95 41.89 to 57.21 0.8979
CRO-I 91.59 79.94 to 104.9 0.8855
430 142.1 120.0 to 168.4 0.9592
385 143.2 123.1 to 166.7 0.94
416 199.6 132.0 to 301.8 0.8856
1.2 207.2 111.1 to 386.6 0.5836
18 251 215.0 to 293.0 0.8518
398 304.8 258.1 to 360.1 0.9439
438 436.9 383.5 to 497.7 0.9666
389 613.4 403.4 to 932.6 0.7345
432 1299 702.6 to 2403 0.6504
85 1560 1077 to 2261 0.381
417 9954 2472 to 40084 0.6524
383 * >1000
* model convergence failed
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Figure 3: Treatment of CRC-SCs with UCN-01 enhances the effects of irinotecan in vivo. Tumor volume increase curves 
in NSG mice xenografted with a KRAS wild-type (#1.1) or mutant (#18) CRC-SC treated by i.p. injection with either vehicle (DMSO), 
UCN-01 (5mg/Kg), irinotecan (10mg/Kg) or combined UCN-01 and irinotecan. Values are reported, for each cell line and drug tested, as 
the mean±SD of two independent experiments each comprising two biological replicates. Statistical comparison of UCN-01 or irinotecan 
alone versus irinotecan/UCN-01 combination is reported for the latest time point and was calculated by means of two-way ANOVA and 
Tukey’s multiple comparisons test.
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Cytotoxic effects of UCN-01 involve Chk1 
inhibition
To further analyse the molecular mechanisms 
through which UCN-01 exterts its cytotoxic effects, we 
evaluated DNA cell content in CRC-SCs treated with 
UCN-01 alone or in combination with irinotecan. A 
consistent increase in the pre-G
0
 peak and the S phase was 
apparent in the cell lines tested and, particularly in line 
#1.1 where inhibition of in vitro cell growth was more 
evident. Pre-G
0
 peak increase indicates that induction of 
apoptosis significantly contributes to the cytotoxic effect 
of UCN-01 (Figure 4A).
Although UCN-01 is widely recognized as a broad-
spectrum inhibitor of the PKC family of enzymes, it has 
also been demonstrated that one of its preferential targets 
is the checkpoint kinase Chk1, directly acting on the dual-
specificity phosphatase CDC25C, as well as on PDK1, 
which acts upstream of AKT. In order to understand 
whether such signaling pathway contributes to the effect 
of UCN-01 on CRC-SCs, we evaluated the expression 
levels of total and phosphorylated PDK1 (pS241), PKCα/β 
II (pT638/41), CDC25C (pS216) and Chk1 (pS345) in two 
representative CRC-SC lines. Immunoblotting analysis 
demonstrated that UCN-01 alone or in combination with 
irinotecan affects the ATR-mediated phosphorylation of 
Chk1 and PKC directly blocking the activation of the Chk1 
target CDC25C (Figure 4B), confirming the contribution 
of several targets in determining the response of CRC-SCs 
to UCN-01. PDK1 phosphorylation was slightly reduced 
in both cell lines by the combination of UCN-01 and 
irinotecan. Chk1 phosphorylation has been described to 
be a useful biomarker for monitoring inhibition of Chk1 
activity, both in vitro and in clinical trials [25]. However, 
growing evidences show that, treatment with cytotoxic 
chemotherapeutic agents as well as Chk1 inhibitors, may 
result in a marked reduction of total and phosphorylated 
Chk1 [25]. Moreover, it has been demonstrated that 
inhibition of Chk1 activity paradoxically leads to the 
accumulation of its phosphorylated forms (pS317 and 
pS345) and that ATR catalyzes Chk1 phosphorylation 
under these conditions [26]. In line with these observations 
we found that combination of UCN-01 with irinotecan 
is able to significantly reduce both total and phospho-
Chk1 (pS345) in the KRAS/TP53 mutant CRC-SC line 
#18. Conversely, levels of phosphorylated Chk1 (pS345) 
slightly increased in the KRAS/TP53 wild type CRC-SC 
line #1.1 (Figure 4B).
In line with the ability of UCN-01 to enhance the 
pro-apoptotic signals induced by irinotecan, the expression 
of anti-apoptotic proteins BCL-X
L
 and MCL1 were 
decreased by co-treatment with UCN-01 but only in the 
KRAS wt CRC-SC line (Figure 4B).
In order to gain additional insights into the 
molecular mechanisms behind the enhanced cytotoxic 
effects of UCN-01/irinotecan combination, we studied 
the activation status of other proteins involved in DNA-
damage, PI3K/mTOR, AMPK, MAPKs and TGF-β 
signaling pathways by RPPA. Phosphorylation status 
of the RPPA endpoints analysed in four CRC-SC lines 
showed heterogeneous patterns of pathway activation 
and no clear association with the sensitivity to single 
agents or combined treatment at specific timepoints 
and drug concentrations (Supplementary Figures S3 
and S4). Nonetheless, dose-response analysis of the 
molecular changes caused by both single and combined 
treatments, demonstrated that UCN-01 might either 
reinforce or amplify the action of irinotecan on CRC-SCs 
by modulating diverse components of the DNA damage/
Cell cycle checkpoint (Figure 4C and Supplementary 
Figures S3 and S4). These observations induced us to test 
the effects of a commercially available Chk1/2 inhibitor, 
i.e. LY2603618, either as a single agent or in combination 
with irinotecan on CRC-SCs. Concomitant treatment 
with the Chk1/2 inhibitor significantly increased the 
ability of irinotecan to inhibit in vitro cell proliferation of 
both KRAS wild type and mutant CRC-SC lines (Figure 
5A). Moreover, combined treatment was effective in 
inhibiting in vivo tumor growth of KRAS/TP53 mutant 
CRC-SC line. (Figure 5B). The LY2603618 activity as a 
single agent or combined with irinotecan was evaluated 
by immunoblot showing a modulation of both total 
and phosphorylated Chk1 and its downstream effector 
Cyclin-dependent Kinase 1 (CDK1, also known as 
CDC2). LY2603618 did not potentiate the reduction of 
phosphorylated and total PDK1 or PKC levels induced 
by irinotecan (Supplementary Figure S5). Treatment 
with LY2603618, did not result in a marked activation 
of caspase 3 as assessed by immunoblot analysis 
(Supplementary Figure S5).
Finally, since Chk1 is the target of ATR kinase 
activity, we tested AZ20, a novel, potent and selective 
inhibitor of ATR kinase (IC50 5nM), on two CRC-SC 
lines using time/concentration conditions employed for 
UCN-01 and LY2603618. As shown in Supplementary 
Figure S6 AZ20 alone or in combination with irinotecan 
exerts cytotoxic effects similar, in CRC-SC line 
#18, or reduced, in CRC-SC line #1.1, compared to 
LY2603618.
Taken together these results confirm that 
concomitant inhibition of DNA damage and DNA 
replication pathways increases the efficacy of conventional 
chemotherapy on CRC-SCs.
DISCUSSION
In recent years there has been a rapid increase in 
therapeutically available approaches for CRC and this, 
in turn, has led to an improvement of overall patients’ 
survival. Irinotecan or oxaliplatin introduced into the 
clinics more than ten years ago, in association with 5-FU 
and folinic acid, remain the main therapeutic options for 
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Figure 4: Combination of UCN-01 with irinotecan blocks CRC-SC replication by targeting the DNA damage pathway. 
A. Cell cycle analysis of two representative CRC-SCs after 48h treatment with two different doses of UCN-01 (250 and 500nM, respectively 
01 and 02) or irinotecan (12.5 and 25 μM, respectively 01 and 02) and their combinations. B. Western blot analysis of UCN-01 targets 
and BCL2 family proteins after 48h treatment with UCN-01, irinotecan or their combination (doses are 500nM and 25 μM, respectively). 
C. Time course plots of RPPA data obtained on 4 CRC-SCs after 24h treatment with UCN-01, irinotecan and their combinations at the 
indicated concentrations. Data are expressed in percent calculated over the vehicle control (DMSO 0.1%).
Oncotarget44122www.impactjournals.com/oncotarget
CRC patients in advanced stage even if response to these 
treatments is not always definitive, with a mean 5-year 
survival rate of about 40% [27, 28].
Recently characterized aberrant/hyperactive signaling 
pathways in CRC led to the understanding of molecular 
mechanisms behind initiation and progression of such 
neoplasm and allowed the identification of potential 
molecular targets and predictors for new therapies [29]. 
Protein kinases represent an important group of enzymes 
crucially involved in controlling survival and tumor 
progression signals and their inhibition is conventionally 
obtained by two main classes of compounds: monoclonal 
Figure 5: Treatment with the Chk1/2 inhibitor LY2603618 enhances the efficacy of irinotecan in vitro and in vivo. 
A. Mean±SD (n=3) bar chart of 48h combinatorial treatment of LY2603618 (250 and 500 nM) and irinotecan (12.5 and 25 μM) in two 
representative CRC-SC lines. Statistical comparison of LY2603618 alone versus LY2603618/irinotecan combination was done by means of 
one way ANOVA and Tukey's multiple comparisons test, levels of significance are indicated on top of the relative bars. B. Mean±SD (n=2) 
of normalized tumor volumes (see Materials and Methods section) in NSG-mouse xenografts of the KRAS mutant CRC-SC line #18 after 
i.p. treatment with either vehicle (DMSO), LY2603618 (5mg/Kg), irinotecan (10mg/Kg) or combination of LY2603618 and irinotecan. 
Statistical comparison of LY2603618 or irinotecan alone versus irinotecan/LY2603618 combination for the latest time point was done by 
means of two-way repeated measures ANOVA and Tukey’s multiple comparisons test.
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antibodies, acting mainly by competition with natural 
ligands on cell surface tyrosine kinase (TK) receptors, and 
small molecule inhibitors of natural or synthetic origin, 
acting also on intracellular enzymes/receptors. The use 
of these compounds has been applied to CRC treatment, 
in order to selectively inhibit tumor-associated activity 
of kinases such as EGFR, VEGFR, PDGFR, PI3K and 
mTOR [30]. Although targeted therapy has produced a 
significant increase in progression free survival of CRC 
patients, present clinical protocols are still ineffective in 
definitively eradicating the tumor in advanced cases [31]. 
The limited efficacy of currently available anti-cancer 
therapies has recently been linked to the possibility, 
supported by a growing body of evidence, that cancer is 
a stem cell disease. In particular, the recent identification 
of cell populations bearing stem cells characteristics in 
human tumors, including CRC, suggested that these might 
originate from a small fraction of tumor cells, referred to as 
“cancer stem cells” (CSC) [11, 12]. CSCs are characterized 
by self-renewal ability, multipotency and tumorigenicity 
in permissive hosts but also display low sensitivity to 
chemotherapy [32, 33] and radiotherapy [34] and are 
capable of initiate tumor growth in the original or in distant 
sites [18]. Therefore, CSCs are a target of choice for novel 
selective therapies aimed at a complete tumor eradication. 
The comprehension of CRC-SC behavior and, in particular, 
of the molecular mechanisms that regulate self-renewal, 
survival, apoptosis, proliferation and differentiation is of 
major interest to induce their efficient elimination and, in 
turn, a complete tumor regression. To this aim, we screened 
our CRC-SC lines with a library including 80 protein kinase 
inhibitors with characterized target specificity. This analysis 
led to the identification of critical pathways potentially 
involved in proliferation and survival of CRC-SC such as 
EGFR, AKT, MEK, PKC, PDGFR and GSK3-β. However, 
scaling down to sub-micromolar concentrations, most 
positive hits from the high-concentration screening failed 
in maintaining their efficacy. Treatment with compounds 
analogues of the drugs that kept efficacy at reduced doses 
demonstrated that, differently from all other molecules 
tested in this study, UCN-01 is able to efficiently induce 
cell death and to increase the cytotoxicity of irinotecan in 
CRC-SCs with diverse genetic background. UCN-01 is a 
staurosporine derivative that, differently from its parent 
molecule, displays significant activity against a handful 
of kinases. Initially identified as a PKC inhibitor, UCN-01 
also targets Chk1 and PDK1 [35]. Notably, the efficacy of 
UCN-01 as an antineoplastic agent in combination with 
chemotherapy, has been evaluated in phase I and II clinical 
trials on solid tumors [36-39].
Although CSCs play an important role in CRC 
progression and growth, conventional treatment for CRC 
is required to eliminate the aberrantly proliferating cells 
that form the bulk of the tumor and is important also 
because inter-conversion between non-stem and stem 
status has been described [40, 41]. In our hands, UCN-01 
affected the viability of CRC-SCs by increasing irinotecan 
cytotoxicity and inducing cell death. SN-38, the most 
active metabolite of irinotecan, is known to produce 
DNA damage by blocking topoisomerase I and triggering, 
by itself, a p53-dependent apoptotic response [42, 43]. 
Indeed, following irinotecan treatment, we observed 
decrease of full-lenght Caspase-3 and of its target PARP. 
Combination with UCN-01 further increased PARP 
cleavage and simultaneously reduced the levels of the anti-
apoptotic proteins upregulated by PKCα [44, 45], BCL-X
L
 
and MCL1, the latter only in the KRAS wt cell line, thus 
suggesting a potential mechanism for the additive effects 
of UCN-01 and irinotecan.
Another UCN-01 target, PDK1 is known to act 
upstream of the PI3K/AKT pathway promoting the 
expression of BCL-2 family proteins [46]. Here, UCN-
01 treatment contributes to enhance apoptosis induced 
by irinotecan possibly through the marked reduction of 
PDK1 auto-phosphorylation (pS241). In vivo analysis 
of UCN-01 sensitivity in murine heterotopic xenograft 
models of CRC-SC growth, confirmed our previous 
in vitro observations, demonstrating that UCN-01/
irinotecan combination significantly impairs tumor 
growth compared to chemotherapy alone. RPPA analysis 
of the molecular mechanisms underlying the enhanced 
cytotoxic effects of UCN-01/irinotecan combination 
showed that many components of the DNA damage/cell 
cycle checkpoint are affected. Particularly, even though 
the four CRC-SC lines showed heterogeneous patterns 
of pathway activation and no clear association with 
the sensitivity to single agents or combined treatment 
at specific timepoints and drug concentrations, we 
found a specific inhibition of Chk1 kinase and its main 
targets, i.e. CDC25C phosphatase and CDK1 (CDC2). 
Thus, we hypothesize that the impairment of CRC-SC 
growth both in vitro and in vivo is associated with Chk1 
targeting. Chk1 phosphorylates CDC25C in response to 
DNA damage and following replication fork stalling, 
thus preventing cell cycle advancement and allowing 
repair of DNA damage induced by chemotherapy in 
CSCs [47, 48]. Accordingly, it has been demonstrated 
in a commercial CRC line model that irinotecan/UCN-
01 treatment is effective only in the absence of TP53 or 
CDKN1A (p21) or both [43]. In the context of CSCs, 
the additive effects showed by UCN-01/irinotecan 
combination could result from the interference with CSC 
responses to chemotherapy-induced genotoxic stress 
irrespective of TP53 status. Nonetheless, co-treatment 
with the selective Chk1/2 inhibitor LY2603618, was 
able to potentiate irinotecan efficacy in vitro and in our 
mouse model of CRC growth, confirming a pivotal role 
of Chk1 in this context.
Altogether our data obtained on a CRC-SC-based 
model system indicate that Chk1 inhibition potentiates the 
antitumor activity of standard chemotherapeutic agents 
and potentially may address resistance to them.
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MATERIALS AND METHODS
CRC and CRC-SC lines
HCT116 and SW480 CRC cell lines were purchased 
from American Type Culture Collection (ATCC) and 
cultivated in the recommended media (see www.atcc.org 
for details).
CRC samples were obtained from Sant’Andrea 
Hospital (Rome) upon patients’ informed consent, the 
procedure was approved by the local ethical committee. 
CRC-SCs were isolated as previously described [12]. 
Briefly, tumor samples were subjected to mechanical and 
enzymatic dissociation using type II collagenase (Gibco 
Invitrogen Inc., BRL, Rockville, MD) and DNase I 
(Roche, Mannheim, Germany). The resulting cancer cells 
were cultured in a serum-free medium supplemented with 
20 ng/ml EGF and 10 ng/ml FGF-2 (PeproTech, Rocky 
Hill, NY). The expression of the stem cell marker CD133 
and epithelial marker Ber-Ep4 have been evaluated by flow 
cytometry using the following antibodies: anti-CD133-
PE (clone AC133/1, mouse IgG1, MiltenyiBiotec Inc., 
Bergisch Gladbach, Germany), anti-Epithelial Antigen-
FITC (clone Ber-Ep4, mouse IgG1, DakoCytomation, 
Denmark) or isotype-matched control antibodies. Samples 
were analyzed with FACSCanto flow cytometer (Becton 
Dickinson, San Jose, CA) and data were analyzed with 
FACS Diva software (Becton Dickinson).
The ability to reproduce the original tumor has been 
evaluated by subcutaneous (s.c.) injection of CRC-SCs in 
immunodeficient NOD/SCID (Harlan Laboratories Italia, 
San Pietro al Natisone, Italy) or NOD/SCID IL2-Rγ-(NSG) 
mice (Charles River Italia, Calco, Italy). Tumors were 
removed, fixed in 10% neutral buffered formalin solution 
(Sigma Aldrich Inc., Saint Louis, MO) and paraffin 
embedded for histologic analysis. Supplementary Table 
S1 contains a list of the clinical features of the patients 
from which CRC-SCs were derived and Supplementary 
Figure S1 shows the paired comparison of H&E stainings 
obtained on CRC-SC-derived s.c. xenografts versus their 
original patient’s tumor.
CRC-SC line authentication and genetic 
characterization
CRC-SC lines were validated by Short Tandem 
Repeat (STR) DNA fingerprinting. Nine highly 
polymorphic STR loci plus amelogenin (Cell ID™ 
System, Promega Inc., Madison, WI) were used. Detection 
of amplified fragments was obtained by ABI PRISM 3100 
Genetic Analyzer and data analysis was performed by 
GeneMapper® software, version 4.0 (Biological Bank 
and Cell Factory, National Institute for Cancer Research, 
IST, Genoa, Italy). For all CRC-SC lines, profiles were 
compared against public databases to confirm authenticity.
Single-point mutations and small insertions-
deletions in CRC-SCs were assessed by targeted DNA 
resequencing, focusing on 17 genes known to be frequently 
mutated in colon cancer and to play an important role in 
targeted therapy or prognosis. An amplicon-based custom 
panel was developed by using the Illumina Design-Studio 
software. The library for sequencing was prepared with 
the Truseq Custom Amplicon Kit following basically the 
manufacturer’s instructions. Sequencing was performed 
on a MiSeq instrument.
Sequence FASTQ files were generated and analyzed 
through the MiSeq Reporter pipeline from Illumina. The 
analysis pipeline employs the Banded Smith Waterman 
algorithm 2.5 for read mapping and the Somatic Variant 
Caller (v3.5) for variant calling. Annotation of variants 
was carried out with Illumina Variant Studio software. 
Further in-house scripts were employed for mutation 
filtering and clustering, in particular with a minimum 
coverage of 100x, allele frequency of at least 5% and 
excluding all known SNPs with MAF >=5%. Oncoprints 
were generated with the integration of R scripts available 
at https://github.com/dakl/oncoprint.
Drug cytotoxicity experiments
For cytotoxicity analysis CRC-SCs were 
mechanically dissociated and plated at a density of 2.5x104 
cells/ml, in triplicate, in a 96-well plate. 5-FU, Oxaliplatin 
and UCN-01 were purchased from Sigma, irinotecan and 
the small molecule kinase inhibitor library were from 
Enzo Life Sciences/Biomol (Farmingdale, NY, http://www 
.enzolifesciences.com/BML-2832/kinase-inhibitor-library). 
A list of the compounds used for the library screening is 
available as Supplementary Table S2. ERK inhibitor and 
its negative control (ERK inhibitor FR180204 II, ERK 
inhibitor II-Negative control), Akt and PKC inhibitors 
and the multiple inhibitor (Akt inhibitor II and X, PKC 
inhibitor Set, PDK1/Akt/Flt Dual Pathway Inhibitor) were 
from Calbiochem (Merck KGaA, Darmstadt, Germany), 
OSU-03012 and LY2603618 were from Selleck Chemicals 
(Houston, TX, USA). Compounds were dissolved in 
DMSO and added 16 hours after cell plating. ATP levels 
were measured using the CellTiter-Glo™ (Promega Inc) as 
per the manufacturer’s instructions. The mean of the raw 
luminescence values (LD) from triplicate wells treated with 
vehicle alone (DMSO 0.2%, mLC), was used as reference 
to calculate percent viability from wells treated with drugs 
(VD), using the following formula: VD=(LD/mLC)*100.
Cell cycle assay
For cell cycle analysis, 2x105 CRC-SCs were plated 
in 6-well microtiter plates. After 16h, cells were treated 
with UCN-01 (250-500 nM) and irinotecan (12.5-25 μM) 
alone or in combination, after either at 24 or 48h., CRC-
SCs were resuspended in Nicoletti’s buffer containing 
propidium iodide 50 μg/mL [49].
Samples were analyzed using a FACSCanto flow 
cytometer (Becton Dickinson).
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Western blotting
Total protein content was extracted from cells using 
RIPA buffer (20 mMTris/HCl pH 7.2, 200 mMNaCl, 1% 
NP40) and Protease Inhibitor Cocktail and Phosphatase 
Inhibitor Cocktails II and III (Sigma-Aldrich). Samples 
were resolved in SDS-PAGE gels (NuPage 4-12% bis-
tris Gel, Invitrogen). Protein expression was analyzed by 
standard western blot procedure using anti-Caspase 3 (Cell 
Signaling Technology, Danvers, MA, USA), anti-MCL1, 
anti-BCL-XL (both from Santa Cruz Biotechnology, 
Dallas, TX, USA), anti-PDK1, anti–PDK1_pS241, anti-
PKCα/βII_pT638-41, anti Chk1 and anti-Chk1_pS345 
(all from Cell Signaling Technology). The anti-nucleolin 
(Santa Cruz Biotechnology) or anti-β actin (Sigma 
Aldrich) antibodies were used as loading controls.
CRC xenograft mouse models
Cells were resuspended in cold PBS and the 
suspension mixed with an equal volume of cold Matrigel 
(Becton Dickinson) at a final cell concentration of 5x106 
cells/mL. Mice were injected subcutaneously with 0.2 mL 
of the cell/Matrigel suspension. Treatments were initiated 
when the xenografts reached 10-13 mm in mean diameter, 
a size at which any change can be readily detected by 
caliper. Mice were treated for three weeks with 10mg/Kg 
irinotecan once a week on the first day and/or with 5mg/Kg 
UCN-01 (or with 5mg/Kg LY2603618) for 5 days a week. 
Treated mice were maintained up to 3 weeks without any 
further treatment, except for measurement of tumor mass, 
then sacrificed by cervical dislocation. Controls mice 
received an equal volume of saline/15% DMSO that was 
injected intraperitoneally (i.p.). Tumor growth percentage 
was calculated by normalizing over initial tumor volume. 
Animal experiments were performed in accordance with 
relevant institutional and national regulations.
Reverse-phase protein microarrays
RPPAs were performed as previously described 
[50, 51]. Briefly, on day 0, CRC-SCs were enzymatically 
dissociated (TrypLE Select, Life Technologies Corporation, 
Carlsbad, CA), counted and plated into 24-well microtiter 
plates at a density of 5x105 cells per well. The following day, 
CRC-SCs were treated with UCN-01 (125-250-500 nM) and 
irinotecan (6.25-12.5-25 μM) alone or in combination at all 
doses and cells were lysed either at day 2 (24h) or day 3 
(48h). Cell lysates were diluted with 2X Tris-Glycine SDS 
Sample Buffer (Life Technologies) and final 2.5% TCEP 
(Thermo-Scientific, Whaltman, MA) prior to printing on 
nitrocellulose slides (Grace Bio-Labs, Bend, OR, USA) and 
were spotted in technical triplicates with the Aushon 2470 
contact pin arrayer (AushonBioSystems Inc., Billerica, MA), 
in neat and 1:4 dilution pairs. Positive and negative control 
lysates were printed on every slide in a ten-point two-fold 
dilution curve. A subset of the printed slides were stained 
with by Sypro Ruby Blot Stain (Life Technologies) for 
assessment of total protein concentration. After incubation 
for 2 hours with I-Block (Life Technologies), array staining 
with antibodies was carried out on an automated slide stainer 
(Autostainer CSA kit, DAKO, Carpinteria, CA) using a 
biotin-avidin amplification system per the manufacturer’s 
instructions (CSA kit, DAKO). Biotinylated secondary 
antibody was either goat anti-rabbit IgG H+L (Vector 
Labs, Burlingame, CA) or anti-mouse Ig (from CSA kit, 
DAKO). Streptavidin-conjugated IRDye680LT® (LI-COR 
Biosciences, Lincoln, NE, USA) was used as a final signal 
generating step. Stained slides were scanned on a Tecan 
Power Scanner (Männedorf, Switzerland) equipped with a 
customized emission filter to increase efficiency in collection 
of IRDye680LT® fluorescence. Image analysis for spot 
recognition, quantification and normalization was carried 
out using MicroVigene 5.1 software (VigeneTech Inc., 
Carlisle, MA, USA). Time course plots for all conditions 
and endpoints analysed by RPPA have been included in 
Supplementary Figure S2, after normalization over vehicle 
controls. All antibodies used for RPPA analysis are listed in 
Supplementary Table S3.
Statistical analysis
For RPPA data analysis, unsupervised hierarchical 
clustering (Euclidean distance, Ward.D2 method) was 
performed on standardized data, by means of the package 
‘gplots’ of the “R” software [52]. Plots in the manuscript 
were generated using ‘ggplot2’ package of ‘R’ while 
GraphPad Prism version 4.00 for Windows (GraphPad 
Software, La Jolla California USA, www.graphpad.com) 
was used for plots and non-linear fitting of UCN-01 dose-
response experiments [4-parameter logistic (4PL) model: 
log(inhibitor) vs normalized response with variable slope]. 
Statistical comparison of Chk1 inhibitors alone versus 
combination with irinotecan was done by GraphPad Prism. 
Statistical significance was accepted for p values lower 
than 0.05 and astersiks reported in the plots indicate the 
level of significance as follows: * p<0.05, ** p<0.01, *** 
p<0.001 and **** p<0.0001.
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